HC Wainwright Issues Optimistic Estimate for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, December 15th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.11 per share for the year, up from their previous estimate of $0.09. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2027 earnings at $0.31 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.07) earnings per share.

Several other analysts also recently commented on the stock. Zacks Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday. Finally, Evercore ISI restated an “in-line” rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Ten equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

BioCryst Pharmaceuticals Trading Down 4.6%

Shares of NASDAQ:BCRX opened at $7.13 on Tuesday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. The company has a market cap of $1.50 billion, a PE ratio of -142.60, a price-to-earnings-growth ratio of 0.72 and a beta of 0.91. The company’s 50 day moving average is $7.17 and its 200 day moving average is $8.17.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the transaction, the insider owned 416,152 shares in the company, valued at approximately $2,954,679.20. This represents a 17.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 161,680 shares of company stock valued at $1,164,401 over the last three months. 5.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter worth about $169,000. Voleon Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $816,000. Verition Fund Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 162.4% during the 3rd quarter. Verition Fund Management LLC now owns 57,451 shares of the biotechnology company’s stock worth $436,000 after buying an additional 35,555 shares during the period. Sherbrooke Park Advisers LLC raised its stake in shares of BioCryst Pharmaceuticals by 30.5% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 16,524 shares of the biotechnology company’s stock worth $125,000 after buying an additional 3,866 shares during the period. Finally, Qube Research & Technologies Ltd lifted its position in shares of BioCryst Pharmaceuticals by 1.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 2,410,362 shares of the biotechnology company’s stock valued at $18,295,000 after buying an additional 36,873 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.